Physician profile
Scott Kaufman
NPI 1205819521
$10,816.35
in general payments reported to CMS, 2019-2025
31 companies · $3,410 in 2025
The $3,410 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $337 · 2021: $410 · 2022: $1,098 · 2023: $2,849 · 2024: $2,397 · 2025: $3,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,181 · Travel and Lodging: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,180.62 |
| Travel and Lodging | $2,475.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,746.41 | 2021-2025 | Evera Mri Xt Dr Surescan, Azure Xt Dr Mri Surescan, Micra |
| Abbott Laboratories | $1,497.92 | 2023-2025 | Aveir, Diamondback Peripheral, Nc Trek Neo |
| Boston Scientific Corporation | $716.19 | 2019-2025 | Watchman Flx, Watchman Access System, Rhythmia Mapping System |
| Biosense Webster, INC. | $520.10 | 2022-2025 | Carto 3 |
| Amgen INC. | $406.31 | 2020-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.92 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $311.61 | 2019-2024 | Eliquis, Camzyos |
| Biotronik INC. | $263.16 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $168.37 | 2022-2025 | |
| Pfizer INC. | $114.86 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $112.80 | 2019-2022 | |
| Philips North America LLC | $99.80 | 2019-2021 | |
| Baxter Healthcare | $97.49 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.15 | 2023-2025 | Jardiance |
| Livanova USA, INC. | $32.94 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $32.20 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $30.18 | 2022-2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $28.16 | 2022-2024 | Farxiga |
| Convatec INC. | $24.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.08 | 2024 | |
| Argon Medical Devices, INC. | $20.21 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.96 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $16.24 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $14.89 | 2025 | |
| Scpharmaceuticals INC. | $14.43 | 2025 | |
| Opsens INC. | $14.18 | 2021 | |
| Ethicon US, LLC | $14.16 | 2025 | Dermabond Prineo |
| Lexicon Pharmaceuticals, INC. | $13.24 | 2024 | |
| Irhythm Technologies, INC. | $12.87 | 2023 | Zio Xt Patch |
| Terumo Medical Corporation | $12.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.